Atlas Trials

Study of Gecacitinib in the Treatment of Acute Graft-Versus-Host Disease After Failure of Ruxolitinib-containing Second-line Therapy

Clinical trial NCT07197112 · NOT_YET_RECRUITING

Trial details

NCT number
NCT07197112
Sponsor
Ruijin Hospital
Status
NOT_YET_RECRUITING
Phase
Phase 2
Study type
INTERVENTIONAL
Acute Graft Versus Host Disease Grade II-IVAcute Graft vs Host Disease
Start date
2025-10-01
Primary completion
2027-02-01
Enrollment
15

View on ClinicalTrials.gov

Track trials programmatically

Sponsors, conditions and status changes through the Atlas API.